Experimental immune cell therapy shows promise for Tough-to-Treat colon cancer
NCT ID NCT04444622
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase IIB trial tested an experimental immunotherapy called STIMVAX (AlloStim) in 29 adults with metastatic colorectal cancer that had not responded to two prior chemotherapy regimens. The treatment uses immune cells from healthy donors to try to fight the cancer. The study measured overall survival and safety to see if this approach could be a new option for patients with limited choices.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
STIMVAX (AlloStim) - immune cells from healthy donors
What this could lead to
If successful, this could offer a new treatment option for people with advanced colorectal cancer who have run out of standard chemotherapy options.
What could go wrong
This is a small, early-phase trial (Phase IIB) with only 29 participants, so results may not apply to everyone. The treatment is experimental and may cause side effects or not improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hirschfield Oncology Center
The Bronx, New York, 10469, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Mt. Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
-
Summit Health
Florham Park, New Jersey, 07932, United States